Paralleling effects on cell survival, AICAR leads to dose- and time-dependent inhibition of HER2 and EGFR in HER2-amplified breast cancer cells, with activation of AMPK and suppression of HER2/EGFR activity preceding commitment to cell death. This evidence concerns the gene ERBB2 and breast carcinoma.